These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 31440997)

  • 1. Chronic Rifaximin Use in Cirrhotic Patients Is Associated with Decreased Rate of C. difficile Infection.
    Feuerstadt P; Hong SJ; Brandt LJ
    Dig Dis Sci; 2020 Feb; 65(2):632-638. PubMed ID: 31440997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breakthrough Clostridium difficile Infection in Cirrhotic Patients Receiving Rifaximin.
    Reigadas E; Alcalá L; Gómez J; Marín M; Martin A; Onori R; Muñoz P; Bouza E
    Clin Infect Dis; 2018 Mar; 66(7):1086-1091. PubMed ID: 29069372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MELD is the only predictor of short-term mortality in cirrhotic patients with C. difficile infection.
    Hong SJ; Feuerstadt P; Brandt LJ
    Dig Liver Dis; 2019 Feb; 51(2):275-280. PubMed ID: 30172651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targets to improve quality of care for patients with hepatic encephalopathy: data from a multi-centre cohort.
    Bajaj JS; O'Leary JG; Tandon P; Wong F; Kamath PS; Biggins SW; Garcia-Tsao G; Lai J; Fallon MB; Thuluvath PJ; Vargas HE; Maliakkal B; Subramanian RM; Thacker LR; Reddy KR
    Aliment Pharmacol Ther; 2019 Jun; 49(12):1518-1527. PubMed ID: 31032966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy.
    Bajaj JS; Sikaroodi M; Shamsaddini A; Henseler Z; Santiago-Rodriguez T; Acharya C; Fagan A; Hylemon PB; Fuchs M; Gavis E; Ward T; Knights D; Gillevet PM
    Gut; 2021 Jun; 70(6):1162-1173. PubMed ID: 32998876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rifaximin treatment in hepatic encephalopathy.
    Bass NM; Mullen KD; Sanyal A; Poordad F; Neff G; Leevy CB; Sigal S; Sheikh MY; Beavers K; Frederick T; Teperman L; Hillebrand D; Huang S; Merchant K; Shaw A; Bortey E; Forbes WP
    N Engl J Med; 2010 Mar; 362(12):1071-81. PubMed ID: 20335583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review of the use of rifaximin for Clostridium difficile infections.
    Ng QX; Loke W; Foo NX; Mo Y; Yeo WS; Soh AYS
    Anaerobe; 2019 Feb; 55():35-39. PubMed ID: 30391527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary Prophylaxis to Prevent the Development of Hepatic Encephalopathy in Cirrhotic Patients with Acute Variceal Bleeding.
    Higuera-de-la-Tijera F; Servín-Caamaño AI; Salas-Gordillo F; Pérez-Hernández JL; Abdo-Francis JM; Camacho-Aguilera J; Alla SN; Jiménez-Ponce F
    Can J Gastroenterol Hepatol; 2018; 2018():3015891. PubMed ID: 30079329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Outcomes of Oral Zinc Therapy in Hepatic Encephalopathy Treatment.
    Fritz MK; Mangino AA; Hunt TV; Pitcock CT; Dugan AJ; Karri K; Yarra P
    Ann Pharmacother; 2023 Aug; 57(8):899-906. PubMed ID: 36367093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of rifaximin on the hospital burden and infections in patients with hepatic encephalopathy: a retrospective observational study.
    De Graeve J; Vanderstraeten E; Delvaeye T; De Lepeleere S; De Somer T; Van Steenkiste C
    Acta Gastroenterol Belg; 2022; 85(3):433-437. PubMed ID: 35833904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of rifaximin versus lactulose for reducing the recurrence of overt hepatic encephalopathy and hopitalizations in cirrhosis.
    Irimia R; Trifan A
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):1021-7. PubMed ID: 23700882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Durability of rifaximin response in hepatic encephalopathy.
    Neff GW; Jones M; Broda T; Jonas M; Ravi R; Novick D; Kaiser TE; Kemmer N
    J Clin Gastroenterol; 2012 Feb; 46(2):168-71. PubMed ID: 22011586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overt Hepatic Encephalopathy: Current Pharmacologic Treatments and Improving Clinical Outcomes.
    Rahimi RS; Brown KA; Flamm SL; Brown RS
    Am J Med; 2021 Nov; 134(11):1330-1338. PubMed ID: 34242619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complications of Cirrhosis in Primary Care: Recognition and Management of Hepatic Encephalopathy.
    Flamm SL
    Am J Med Sci; 2018 Sep; 356(3):296-303. PubMed ID: 30286824
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Liu Y; Chen M
    Can J Gastroenterol Hepatol; 2022; 2022():4209442. PubMed ID: 35711246
    [No Abstract]   [Full Text] [Related]  

  • 16. Prognostic significance of hepatic encephalopathy in patients with cirrhosis treated with current standards of care.
    Bohra A; Worland T; Hui S; Terbah R; Farrell A; Robertson M
    World J Gastroenterol; 2020 May; 26(18):2221-2231. PubMed ID: 32476788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and Risk Factors of Recurrent Clostridioides difficile Infection in Patients With Cirrhosis.
    Phatharacharukul P; Purpura RD; Gandhi D; Xu H; Bickett-Burkhart K; Chalasani N; Fischer M; Orman ES
    Clin Transl Gastroenterol; 2020 Jul; 11(7):e00189. PubMed ID: 32675703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibiotics With or Without Rifaximin for Acute Hepatic Encephalopathy in Critically Ill Patients With Cirrhosis: A Double-Blind, Randomized Controlled (ARiE) Trial.
    Kulkarni AV; Avadhanam M; Karandikar P; Rakam K; Gupta A; Simhadri V; Premkumar M; Zuberi AA; Gujjarlapudi D; Narendran R; Shaik S; Sharma M; Iyengar S; Alla M; Venishetty S; Reddy DN; Rao PN
    Am J Gastroenterol; 2024 May; 119(5):864-874. PubMed ID: 37942950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rifaximin plus lactulose versus lactulose alone for reducing the risk of HE recurrence.
    Sanyal AJ; Kowdley KV; Reau NS; Pyrsopoulos NT; Allen C; Heimanson Z; Bajaj JS
    Hepatol Commun; 2024 Jun; 8(6):. PubMed ID: 38727685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for Clostridium difficile infection in cirrhotic patients.
    Yan D; Huang YD; Chen YB; Lv T; Gu SL; Li YT; Huang JR; Li LJ
    Hepatobiliary Pancreat Dis Int; 2019 Jun; 18(3):237-241. PubMed ID: 31029554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.